|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study显示文摘AIM: Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-α), including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA). However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-α, and the impact of these autoantibodies on the treatment outcome of HCV patients.METHODS: We investigated whether parietal cell autoantibodies (PCA) and/or NOSA were related with treatment-outcome in 57 HCV-treated patients (19 sustainedresponders, 16 relapsers, 22 non-responders). Serum samples from patients were studied blindly at three timepoints (entry, end of treatment and end of followup). For the detection of autoantibodies we used indirect immunofluorescence, commercial and in-house ELISAs.RESULTS: Sustained biochemical response was associated with ANA-negativity at the entry or end of follow up. Sustained virological response was associated with the absence of PCA at the entry. Combined virological and biochemical sustained response (CVBSR) was associated with the absence of antinuclear antibodies (ANA) at the end of follow up and PCA-negativity at the entry. Sustained virological and CVBSR were associated with a reduction of ANA and SMA titers during therapy.CONCLUSION: Although PCA and/or NOSA seropositivity should not affect the decision to treat HCV patients, the presence of some of them such as ANA, PCA and SMA before treatment or their increase during therapy with IFN- α may predict a worse response, indicating the need for a closer monitoring during treatment of HCV patients positive for these autoantibodies. | Nikolaos K.Gatselis Sarah P.Georgiadou Nikolaos Tassopoulos Kalliopi Zachou Christos Liaskos Angelos Hatzakis Georgios N.Dalekos | 2005 | World Journal of Gastroenterology2005，11，4： | 10 |
| 2 | Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma显示文摘AIM: To assess serum cartilage oligomeric matrix protein(COMP) as a marker of cirrhosis and risk of progression to hepatocellular carcinoma(HCC). METHODS: A COMP enzyme-linked immunosorbentassay was used to test 187 patients with chronic liver diseases at the time point of first evaluation. The selected patients included 72 with chronic hepatitis B infection, 75 with chronic hepatitis C infection, 22 with primary biliary cirrhosis, 7 with autoimmune hepatitis type 1, and 11 with alcoholic liver disease. Demographic, biochemical, histological and clinical characteristics of the patients were recorded at the first evaluation. One hundred and forty-seven patients were followed for a median [interquartile range(IQR)] duration of 96.5(102) mo. The clinical, biochemical and histological data, as well as the development of cirrhosis, HCC according to internationally accepted criteria and in case of death, a liver-related cause during the follow-up period, were recorded at the electronic database of our clinic. COMP determination was also performed in 43 healthy individuals who served as the control study group.RESULTS: COMP positivity(> 15 U/L) was detected in 22%-36% among chronic liver disease groups. Strikingly, almost 83% of COMP-positive patients were cirrhotic at baseline, independently of cause of liver disease. Among the patients who developed HCC during follow-up, 73.7%(14/19) were COMP positive at baseline. COMP positivity was significantly associated with older age(P < 0.001), advanced fibrosis(P = 0.001) and necroinflammatory activity(P = 0.001), higher aspartate aminotransferase(P < 0.001), alanine aminotransferase(P < 0.02), γ-glutamyl transpeptidase(P = 0.003), alkaline phosphatase(P = 0.001), bilirubin(P < 0.05), international normalized ratio(P = 0.002) and alpha-fetoprotein levels(P < 0.02), and lower albumin(P < 0.001), and platelet count(P = 0.008). COMP levels [median(IQR)] were significantly higher in cirrhotics compared to non-cirrhotics [13.8(7.9) U/L vs 9.8(4.6) U/L, respectively; P < 0.001]. On multivariate logistic regression analysis, COMP-positivity was independently associated only with cirrhosis(OR = 4.40, 95%CI: 1.33-14.69, P = 0.015). Kaplan-Meier analysis showed that COMP positivity was significantly associated with HCC development(P = 0.007) and higher incidence of liver-related death(P < 0.001). CONCLUSION: Elevated COMP levels are strongly associated with cirrhosis and HCC progression. Serum COMP is a new promising non-invasive biomarker for HCC risk assessment in surveillance programs. | Gary L Norman Nikolaos K Gatselis Zakera Shums Christos Liaskos Dimitrios P Bogdanos George K Koukoulis George N Dalekos | 2015 | World Journal of Hepatology2015，7，14： | 7 |
| 3 | Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients显示文摘AIM:To determine the prevalence and significance of primary biliary cirrhosis (PBC)-specific autoantibodies in firstdegree relatives (FDRs) of Greek PBC patients. METHODS:The presence of antimitochondrial antibodies (AMA) and PBCspecific antinuclear antibodies (ANA) were determined using indirect immunofluores-cence assays, dot-blot assays, and molecularly based enzyme-linked immunosorbent assays in 101 asymp-tomatic for liver-related symptoms FDRs of 44 PBCpatients. In order to specify our results, the same investigation was performed in 40 healthy controls and in a disease control group consisting of 40 asymptomatic for liver-related symptoms FDRs of patients with other autoimmune liver diseases namely, autoimmune hepati-tis-1 or primary sclerosing cholangitis (AIH-1/PSC). RESULTS: AMA positivity was observed in 19 (only 4 with abnormal liver function tests) FDRs of PBC patients and none of the healthy controls. The preva-lence of AMA was significantly higher in FDRs of PBC patients than in AIH-1/PSC FDRs and healthy controls [18.8%, 95% confidence interval (CI):12%-28.1% vs 2.5%, 95% CI:0.1%-14.7%, P = 0.01; 18.8%, 95% CI:12%-28.1% vs 0%, 95% CI: 0%-10.9%, P = 0.003, respectively]. PBC-specific ANA positivity was observed in only one FDR from a PSC patient. Multivariate analysis showed that having a proband with PBC independently associated with AMA positivity (odds ratio: 11.24, 95% CI:1.27-25.34, P = 0.03) whereas among the investigated comorbidities and risk factors, a positive past history for urinary tract infections (UTI) was also independently associated with AMA detection in FDRs of PBC patients (odds ratio:3.92, 95% CI:1.25-12.35,P = 0.02). CONCLUSION:In FDRs of Greek PBC patients, AMA prevalence is significantly increased and independently associated with past UTI. PBC-specific ANA were not detected in anyone of PBC FDRs. | Theodoros A Zografos Nikolaos Gatselis Kalliopi Zachou Christos Liaskos Stella Gabeta George K Koukoulis George N Dalekos | 2012 | World Journal of Gastroenterology2012，18，34： | 4 |
| 4 | IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases显示文摘 | Stella Gabeta Gary L. Norman Nikolaos Gatselis Christos Liaskos Panagiotis A. Papamichalis Athanasios Garagounis Kalliopi Zachou Eirini I. Rigopoulou George N. Dalekos | 2008 | Journal of Clinical Immunology2008，，5： | 2 |
| 5 | Diagnostic Relevance and Clinical Significance of the New Enhanced Performance M2 (MIT3) ELISA for the Detection of IgA and IgG Antimitochondrial Antibodies in Primary Biliary Cirrhosis显示文摘 | Stella Gabeta Gary L. Norman Christos Liaskos Panagiotis A. Papamichalis Theodoros Zografos Athanasios Garagounis Eirini I. Rigopoulou George N. Dalekos | 2007 | Journal of Clinical Immunology2007，，4： | 2 |
| 6 | N: Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview显示文摘 | Dalekos G N Zachou K Liaskos C | 2002 | Eur J Intern Med2002，13，： | 1 |
| 7 | The antiphospholipid syndrome and infection显示文摘 | Georgios N. Dalekos MD Kalliopi Zachou MD Christos Liaskos MD | 2001 | Current Rheumatology Reports2001，，4： | 1 |
| 8 | Representing and reasoning about preferences in requirements engineering显示文摘 | Liaskos S McIlraith S A Sohrabi S | 2011 | Requirements Engi- neering2011，16，3： | 1 |
| 9 | Atoantibodies and defined target autoantigens in autoimmune hepatitis:an owriview显示文摘 | Daiekos GN Zachou K Liaskos C | 2002 | Ear J Intern Med2002，13，3： | 1 |
| 10 | Autoantibodies and defined target autoantigens in autoimmune hepatitis : an overview 显示文摘 | Dalekos G N Zachou K Liaskos C el al | 2002 | Eur J Intern Med2002，13，3： | 1 |
| 11 | Diagnostic relevance and clinical significance of the new enhanced performance M2(MIT3)ELISA for the detection of IgA and IgG anti-mitochondrial antibodies in primary biliary cirrhosis显示文摘 | Gabeta S Norman GL Liaskos C | 2007 | Clin Immunol2007，27，： | 1 |
| 12 | A study of glycemic re- sponse to corinthian raisins in healthy subjects and in type 2 dia- betes mellitus patients显示文摘 | Kanellos P T Kaliora A C Liaskos C | 2013 | Plant Foods for Human Nutrition2013，68，2： | 1 |
| 13 | Autoantibodies and defined target autoantigens in autoimmune hepatitis: an ovew 显示文摘 | Dalekos GN Zachou K Liaskos C | 2002 | Eur J Intern Med2002，，： | 1 |
| 14 | Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta 2- glycoprotein I cofactor or features of antiphospholipid syndrome 显示文摘 | Zachou K Liaskos C Christodoulou DK et aI | 2005 | Eur J Olin lnvestig2005，53，2： | 1 |
| 15 | p38 mitogen-activated pro- tein kinase (p38 MAPK)-mediated autoimmunity:lessons to learn from ANCA vasculitis and pemphigus vulgaris显示文摘 | Mavropoulos A Orfanidou T Liaskos C | 2013 | Autoimmun Rev2013，12，5： | 1 |
| 16 | Autoantibodies and defined target autoantigens in autoimmune hepatitis : an overview 显示文摘 | Dalekos GN Zachou K Liaskos C | 2002 | Eur J Intern Med2002，13，5： | 1 |
| 17 | Autoantihodies and defined target autoantigens in autoimmune hepstitis: anoverview显示文摘 | Dalekos GN Zachou K Liaskos C | 2002 | Eur J Intern Med2002，13，3： | 1 |
| 18 | Adiponectin:a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C显示文摘 | ZOGRAFOS T A LIASKOS C RIGOPOULOU E I | 2008 | Am J Gastroenterol2008，103，： | 1 |
| 19 | Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview 显示文摘 | Dalekos GN Zachou K Liaskos C | 2002 | Eur J Intern Med2002，13，5： | 1 |
| 20 | “Onabotulinumtoxin A significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium” 显示文摘 | COLLINS VM DALY DM LIASKOS M | 2013 | BJU Int2013，112，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员